Overview

Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

Status:
Recruiting

Trial end date:
2023-03-30

Target enrollment:

Participant gender:

Summary

This study will be conducted to evaluate the efficacy of GWP42003-P, compared with placebo, in reducing symptom severity in children with Autism Spectrum Disorder (ASD).

Phase:

Phase 2

Details

Lead Sponsor:

GW Research Ltd

Treatments:

Cannabidiol
Epidiolex